Arecor's Tetris launches hypoglycaemia treatment in Germany

Biopharmaceutical company Arecor Therapeutics announced on Tuesday that its subsidiary Tetris Pharma has launched the ‘Ogluo’ glucagon-prefilled autoinjector pen as a treatment for severe hypoglycaemia in children and adults living with diabetes in Germany.

The AIM-traded firm said Germany is a “significant” diabetes market, and represented the first launch of Ogluo in the European Union.

Ogluo was described as a ready-to-use, ambiently-stored preparation of glucagon that was specifically designed for patients living with diabetes with severe hypoglycaemia, with an estimated 6.2 million adults living with diabetes in Germany.

The treatment’s pricing had been published in the ‘LAUER-TAXE’, the reference for all German pharmacies, insurers, and wholesalers.

Tetris said the launch in Germany built on the roll-out of Ogluo in Great Britain, adding that as part of its pan-European commercialisation programme, it intended to commercialise Ogluo in more “core” European markets.

The company was currently in discussions with various health authorities across Europe to ensure timely launches.

“With the launch of Ogluo in Germany, Tetris Pharma has achieved a significant milestone through the commercialisation of our flagship product,” said Tetris managing director Dr Shafiq Choudhary.

“A severe hypoglycaemic event can be very frightening, not only for the patients, but for those around them who have to act quickly.

“The launch of Ogluo means that patients living with diabetes in Germany who may experience severe hypoglycaemia will now have a new option to tackle those events.”

At 1554 GMT, shares in Arecor Therapeutics were down 6.38% at 220p.

Reporting by Josh White for Sharecast.com.